PRP and Stem Cells Update

 

People are always looking for the latest miracle cure for their ailments. Not a week goes by when someone doesn’t ask me “What’s new in Orthopedics?”

The conversation usually gravitates to the issue of PRP and Stem cells. Platelet Rich Plasma (PRP) and Stem cells are the latest treatments that have moved on from the secret world of rich athletes and celebrities to your neighborhood doctor. The proof of the effectiveness of these treatments is still lacking but the availability is not – if you can afford the price (insurance does not cover these treatments).

Scott A. Rodeo, M.D., of the world famous Hospital for Special Surgery in New York, spoke on this subject at this year’s American Academy of Orthopaedic Surgeons Annual Meeting in New Orleans, a meeting I attended. Rodeo gave six reasons for the increased interest in these new treatments:

  1. Consumer demand, with patients frequently asking about and requesting these approaches
  2. Aggressive marketing, contributing to the demand
  3. A low regulatory bar for many of these agents
  4. The autologous nature that makes many approaches largely safe
  5. Some early, positive data demonstrating symptom modification (but few data for structure modification)
  6. A lack of effective therapeutic alternatives for many soft-tissue injuries

 

“There is little regulation and some early positive data, and we don’t have great solutions as clinicians for some of our patients’ problems. This creates a perfect storm that leads patients to seek these various treatments,” Dr. Rodeo said.

There is wide variability in the formulations used to treat patients. Among the formulations used for treatment under the PRP umbrella are pure platelet-rich plasma, platelet-leukocyte rich plasma, pure platelet-rich fibrin, and leukocyte-and-platelet-rich fibrin. Other blood derivatives, including autologous conditioned serum and autologous protein solution (APS) also have therapeutic potential. With all these various formulations being used, it is difficult to get meaningful conclusions from comparison of outcomes.

While these preparations have potential, there is a lot of work yet to be done to identify the goals of treatment and the most effective formulation for each condition. The wrong formulation for the right condition being treated is destined to failure. The right formulation for the wrong condition will be equally ineffective.

This “trial and error” approach is inefficient, wasteful, and expensive. Successful treatment becomes more luck than science. Terry Stanton, reporting for AAOS Now, tells us what we do know as of 2018:

  1. Tendinopathy: A positive effect is seen for leukocyte-rich PRP systems compared to leukocyte-poor PRP.
  2. Rotator cuff repair: A positive effect is seen in some studies using leukocyte-poor PRP; leukocyte-rich PRP and platelet-rich fibrin matrix are not effective.
  3. Anterior cruciate ligament surgery: PRP does not affect graft-tunnel healing; PRP may accelerate graft maturation; there is no effect on clinical outcomes.
  4. Knee osteoarthritis : Leukocyte-poor PRP has a positive effect on symptoms, not structure.
  5. Meniscus : Arthroscopic repair with platelet-rich fibrin matrix has no effect at two years; in open repair of horizontal tear, the PRP group was better for Knee Injury and Osteoarthritis Outcome Score (KOOS) subscales for pain and sports.
  6. Hamstring injury: One of three randomized clinical trials showed beneficial effect of PRP over control for full recovery significantly earlier than physiotherapy alone; no other study found any significant difference between PRP and autologous blood, placebo injection, or platelet-poor plasma.

 

There is much potential in these biologic treatments, but until the science is better understood and clinical trials have produced better data, these treatments will remain an “expensive shot in the dark.”

 

Trump Improvements in ObamaCare Helping Millions

 

There are two sides to every story. The left is happy to tell you about those who have benefited from ObamaCare – and there are many. But what about those who are worse off now than before?

Alex M. Azar, II, the new Secretary of Health and Human Services (HHS), tells both stories in an Op-ed for The Washington Post. He says that ObamaCare effectively split the United States individual insurance market in two.

The first group, the one progressives boast about, consists of about 8 million enrollees (2017) who pay, on average, less than 25% of the cost of their healthcare insurance. These are the ones who receive taxpayer subsidies that insulate them from the high ObamaCare premiums. Naturally, they think ObamaCare is great!

The other group, the one the media ignores, consists of about 5 million Americans (2017) who face the full brunt of premium increases driven up by the law’s broken regulations. These people pay those premiums without subsidies.

There is actually a third group of about 28 million other Americans who remain uninsured because they don’t qualify for subsidies or Medicaid, but they can’t afford, (or don’t choose to purchase), ObamaCare insurance. The rest of the country receives their healthcare insurance through their employer (178 million) or they qualify for Medicaid, Medicare, or other government funded insurance.

Azar says the subsidized group has remained fairly steady as premiums continued to rise – because subsidies have risen to make up the difference. The total number insured, however, is less than half of earlier expectations of the Obama administration.

But those who don’t receive subsidies have opted out of the system in increasing numbers. An independent analysis found that the entire unsubsidized individual insurance market shrank by more than 40 percent from the first quarter of 2016 to the first quarter of 2018. In other words, ObamaCare has forced unsubsidized Americans to choose between unaffordable insurance and no insurance at all.

Fortunately, the Trump administration finds this unacceptable and has been doing something about it, despite the ineptness of Congress. They have taken the following steps to ameliorate the situation:

  • Short-term, limited duration plans (STLD) – These plans are free from most ObamaCare regulations, lowering their costs by 50 – 80 percent.
  • Renewable plans – These plans allow consumers to stay on their affordable coverage for up to 36 months and lock in low rates in their plans even if they get sick.
  • Ending the Individual Mandate – President Trump has already signed the legislation that will eliminate the onerous Individual Mandate, that forced all Americans to purchase healthcare insurance or pay a tax penalty, beginning in 2019.
  • Association Health Plans – The Trump administration Labor Department has made it easier for small businesses and self-employed Americans to band together to purchase more affordable insurance through these plans. (see earlier post ObamaCare Relief for Small Business)

 

As a result of these steps, the Trump administration has made healthcare insurance affordable again for millions of Americans. They have given people choices that fit into their unique situation instead of offering them the “one size fits all” approach of ObamaCare. While I still believe ObamaCare needs to be repealed and replaced with a better system, these steps go a long way toward improving the current healthcare insurance market.